Vimal Derebail, MD, MPH

Vimal Derebail, MD, MPH

6005 Burnett-Womack
Office: 919-445-2637
Appts: 984-974-5706

UNC Health Care Profile

Assistant Professor of Medicine

Specialty Areas: Management of acute and chronic kidney disease, thrombotic disorders, glomerulonephritis, epidemiology.

Chronology: BS Cum Laude: Duke University, 1997; MD: Medical College of Georgia, 2002; Resident: University of North Carolina, 2002-2005; Clinical Assistant Professor of Medicine: University of North Carolina 2005-2006; Nephrology Fellow: University of North Carolina, 2006-2009; MPH: University of North Carolina, 2010; Research Fellow: University of North Carolina, 2009-2010; Assistant Professor of Medicine: University of North Carolina, 2010-present; Medical Director: Carolina Dialysis-Siler City, 2013-present.

Dr. Derebail’s research interests include understanding the association and pathophysiology of thrombotic disorders in glomerular disease and end-stage renal disease, evaluating the impact of hemoglobinopathies upon renal disease, kidney disease in sickle cell disease and defining novel risk factors for progression of renal disease.  He is also involved in the management of end-stage kidney disease patients at the University of North Carolina in dialysis centers in Carrboro, Pittsboro and Siler City, NC.

Read more about Dr. Derebail's research here.

Selected Bibliography:

Key, NS, Connes P, Derebail VK. Negative health implications of sickle cell trait in high income countries: from the football field to the laboratory. British Journal of Haematology. 2015 Jul;170(1):5-14.

Folsom AR, Tang W, Roetker NS, Kshirsagar AV, Derebail VK, et al. Prospective study of sickle cell trait and venous thromboembolism incidence. Journal of Thrombosis and Haemostasis : JTH. 2015; 13(1):2-9. NIHMSID: NIHMS642687.

Naik RP, Derebail VK, Grams ME, Franceschini N, Auer PL, et al. Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans. JAMA. 2014; 312(20):2115-25. NIHMSID: NIHMS663903.

Caughey MC, Loehr LR, Key NS, Derebail VK, Gottesman RF, et al. Sickle cell trait and incident ischemic stroke in the Atherosclerosis Risk in Communities study. Stroke; a journal of cerebral circulation. 2014; 45(10):2863-7. NIHMSID: NIHMS619114.

Ataga KI, Derebail VK, Archer DR. The glomerulopathy of sickle cell disease. American Journal of Hematology. 2014; 89(9):907-14.

Laurin LP, Nachman PH, Desai PC, Ataga KI, Derebail VK. Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2014; 29(6):1211-8.

Lee T, Biddle AK, Lionaki S, Derebail VK, Barbour SJ, et al. Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy. Kidney International. 2014; 85(6):1412-20. NIHMSID: NIHMS552288.

Lee T, Gasim A, Derebail VK, Chung Y, McGregor JG, et al. Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure. Clinical journal of the American Society of Nephrology : CJASN. 2014; 9(5):905-13.

Derebail VK, Lacson EK Jr, Kshirsagar AV, Key NS, Hogan SL, et al. Sickle trait in African-American hemodialysis patients and higher erythropoiesis-stimulating agent dose. Journal of the American Society of Nephrology : JASN. 2014; 25(4):819-26.

Liapis G, Singh HK, Derebail VK, Gasim AM, Kozlowski T, et al. Diagnostic significance of peritubular capillary basement membrane multilaminations in kidney allografts: old concepts revisited. Transplantation. 2012; 94(6):620-9. NIHMSID: NIHMS475635.

Lionaki S, Derebail VK, Hogan SL, Barbour S, Lee T, et al. Venous thromboembolism in patients with membranous nephropathy. Clinical Journal of the American Society of Nephrology : CJASN. 2012; 7(1):43-51.

Derebail VK, Nachman PH, Key NS, Ansede H, Falk RJ, et al. Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patients. Kidney International. 2011; 80(9):992-9. NIHMSID: NIHMS329902.

Key, NS, Derebail VK.  Sickle cell trait: novel clinical significance. Invited Review. Hematology Am Soc Hematol Educ Program. 2010:418-22.

Derebail VK, Nachman PH, Key NS, Ansede H, Falk RJ, Kshirsagar AV. Brief Communication: High prevalence of sickle cell trait in African-American patients with end-stage renal disease.  J Am Soc Nephrol 2010; 21: 385-6.

Bomback AS, Derebail VK, Shoham DS, Anderson CA, Steffen LM, Rosamond WD, Kshirsagar AV.  Sugar-sweetened soda consumption, hyperuricemia, and kidney disease in the Atherosclerosis Risks in Communities Study.  Kidney Int 2010; 77: 569-70.

Bomback AS, Derebail VK, McGregor JG, Kshirsagar AV, Falk RJ, Nachman PN. Rituximab therapy for membranous nephropathy: a systematic review.  Clin J Am Soc Nephrol 2009; 4: 734-744.

Derebail VK, Parikh P, Jennette JC, Kshirsagar AV. A rare cause of the pulmonary-renal syndrome: a case of atypical haemolytic-uraemic syndrome complicated by pulmonary haemorrhage.  Nephrol Dial Transplant Plus 2008; 6: 417-419.

Pollock DM, Derebail VK, Yamamoto T, Pollock J.  Combined effects of AT(1) and ET(A) receptor antagonists, candesartan, and A-127722 in DOCA-salt hypertensive rats.  Gen Pharmacol 2000; 34(5): 337-342.

Click here for a list of publications on PubMed.